Segment Reporting

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Segment Reporting

13. Segment Reporting

The Company has three reportable segments: Apex, Oxford, and Life Sciences Europe.

The Apex Segment provides information technology and scientific staffing professionals for contract, contract-to-hire and permanent placement positions to Fortune 1000 and mid-market clients across the United States, and offers consulting services for other select project-based needs. Apex Segment provides staffing and services support for companies from all major industries, including financial services, business services, consumer and industrials, technology, government services, and communications.

The Oxford Segment provides high-end contract placement services of information technology and engineering professionals with expertise in specialized information technology, software and hardware engineering, and mechanical, electrical, validation and telecommunications engineering fields. The Oxford Segment also provides direct hire placement services of professionals across many different fields and functions; the majority of its placements are information technology, finance, accounting, sales and engineering professionals.

The Life Sciences Europe Segment provides services of laboratory and scientific professionals to the biotechnology, pharmaceutical, food and beverage, medical device, personal care, chemical and environmental industries. These contract staffing specialties include chemists, clinical research associates, clinical lab assistants, engineers, biologists, biochemists, microbiologists, molecular biologists, food scientists, regulatory affairs specialists, lab assistants and other skilled scientific professionals.

The Company’s management evaluates the performance of each segment primarily based on revenues, gross profit, and operating income. The information in the following tables is derived directly from the segments’ internal financial reporting used for corporate management purposes. The Company's management does not evaluate, manage or measure performance of segments using asset information, and such information is not readily available. Accordingly, assets by reportable segment are not disclosed. The following tables present revenues, gross profit, operating income and amortization by reportable segment (in thousands):

	Three Months Ended March 31, 2015
	Apex		Oxford		Life Sciences Europe		Corporate			Total
Revenues	$	294,293	$	127,471	$	8,281	$	—		$	430,045
Gross profit	79,643		53,524		2,708		—			135,875
Operating income	22,911		15,353		392		(13,585		)	25,071
Amortization	3,522		1,300		47		—			4,869

	Three Months Ended March 31, 2014
	Apex		Oxford		Life Sciences Europe		Corporate			Total
Revenues	$	278,408	$	117,500	$	10,943	$	—		$	406,851
Gross profit	75,506		49,026		3,623		—			128,155
Operating income	22,784		14,284		1,322		(11,882		)	26,508
Amortization	4,089		1,370		71		8			5,538

As described in "Note 3. Discontinued Operations,"the Company sold its Physician Segment on February 1, 2015 and the results of that business are now reported as discontinued operations in the condensed consolidated statements of operations for all periods presented. Accordingly, the Physician Segment is no longer presented in the tables above. Approximately $0.4 million of the previously reported Corporate costs during the first quarter of 2014 were specifically attributed to the Physician Segment and those costs are included in discontinued operations in the condensed consolidated statements of operations.

During the fourth quarter of 2014, the Company closed its European retained search unit. Results for this unit, previously included in the Life Sciences Europe Segment, have been presented as discontinued operations in the condensed consolidated statements of operations and comprehensive income for all periods presented.

The Company operates internationally, with operations mainly in the United States, Europe, and Canada. The following table represents revenues by geographic location (in thousands):

	Three Months Ended
	March 31,
	2015		2014
Revenues:
Domestic	$	410,756	$	386,953
Foreign	19,289		19,898
	$	430,045	$	406,851